Abbott Laboratories Corporation

Abbvie Inc.

Other

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Anthony Ralph Haight

David M Barnes

Hing L Sham

Thomas J Sowin

Timothy L Stuk

Howard E Morton

Chen Zhao

Daniel W Norbeck

Jien-Heh J Tien

Geoff G Z Zhang

M Robert Leanna

Dale J Kempf

Geoff G Zhang

John K Pratt

Rolf Wagner

Dachun Liu

John T Randolph

Todd Warren Rockway

David A Betebenner

Douglas K Hutchinson

Allan C Krueger

Clarence J Maring

Kent D Stewart

Kenton L Longenecker

Pamela L Donner

Yi Gao

Charles A Flentge

Warren M Kati

Steven J Wittenberger

Christopher E Motter

William A Carroll

Marlon D Cowart

Michael D Wendt

Robert J Altenbach

Lawrence A Black

David A DeGoey

Daniel S Reno

Shashank Shekhar

Thaddeus Stephan Franczyk, Ii

Vincent S Chan

Travis B Dunn

Michael S Allen

Timothy A Robbins

David Scarpetti

Linda M Lijewski

Francis A Kerdesky

Laura Melcher

Shuang Chen

Denton C Langridge

Yaya Liu

David A Degoey

Maureen Ann McLaughlin

David R Hill

Margaret Chi-Ping Hsu

Su Yu

Michael G Fickes

Lei Wang

Rodger F Henry

Guo Zhu Zheng

Yi-Yin Ku

Zhonghua Pei

Irene I Drizin

Ahmad Y Sheikh

Minghua Sun

James J Napier

Michael D Tufano

Thomas W Von Geldern

Michael D Meyer

Kirill A Lukin

Steven A King

Lawrence Kolaczkowski

Xiaofeng Li

Russell Drew Cink

Eric Allen Schmitt

Sou-Jen Chang

Fatima Z Basha

Daniel J Plata

David A Riley

James F Kerwin

Nathaniel Catron

Marvin Robert Leanna

Xiaochun Lou

Michael Rasmussen

Jianzhang Mei

Bikshandarkoil A Narayanan

Arthur J Cooper

Eric J Stoner

Gregory S Wayne

Ping Tong

Robert J Gregg

Brian J Kotecki

John E Lallaman

John E Hengeveld

Yeshwant D Sanzgiri

Elaine C Lee

Jufang Barkalow

Jinshyun Ruth Wu-Wong

Prasad S Raje

Tim Grieme

Shyamal I Parekh

This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such compositions.

Process for preparing antiviral compounds

The disclosure is directed to: (a) phosphacycle ligands; (b) catalyst compositions comprising phosphacycle ligands; and (c) methods of using such phosphacycle ligands and catalyst compositions in bond forming reactions.

Phosphine ligands for catalytic reactions

The disclosure is directed to: (a) phosphacycle ligands; (b) methods of using such phosphacycle ligands in bond forming reactions; and (c) methods of preparing phosphacycle ligands.

A process for making 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, and therapeutically acceptable salts thereof, and intermediates used in the process are disclosed.

Preparation of pyridonecarboxylic acid antibacterials

This disclosure is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions.

An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Stabilized lipid formulation of apoptosis promoter

Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.

Octahydro-pyrrolo[3,4-B]pyrrole derivatives

The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Vitamin D receptor activators and methods of making

Growing community of inventors

Wadsworth, IL, United States of America

Anthony Ralph Haight